New approach to promote resolution of inflammation. Developed hybrid compounds that are dual agonists of FPR2 and GPR32.
Dual-Agonist Anti-Inflammatory Compounds
UCD
Last Updated:
Last Updated:
Related News
Innovation Training for ARC Hub for Therapeutics Translational Researchers
To complement excellence in scientific research, successful commercialisation requires research teams to have a strong understanding of their target markets, the specific problems their technologies address, the competitive landscape, and the ability to...
New €31.6 million ARC Hub for Therapeutics to turn breakthrough Irish research into therapies and companies
On December 3rd, 2025, we marked a major milestone for Ireland’s therapeutics ecosystem. The launch of the ARC Hub for Therapeutics was an energising and inspiring day, bringing together a brilliant community of academics, investors, funders, policymakers, and...